UroGen Pharma (FRA:UR8) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


FRA:UR8 UroGen Pharma Ltd FRA:UR8
67 GF Score
Price €29.44
GF Value €17.67
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is UroGen Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

UroGen Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:UR8 vs OCS, SEPN, AVBP: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, UroGen Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Margin of Safety % (DCF Earnings Based) falls into.


FRA:UR8
67GF Score
UroGen Pharma Ltd FRA:UR8
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €29.44 is trading 66.6% above its estimated GF Value™ of €17.67. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €17.67 vs. price of €29.44 (66.6% above fair value)
  • GF Score™: 67/100 with 9 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
67GF Score

Get the complete analysis for FRA:UR8

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.44
Price
€17.67
GF Value